ChemoCentryx Inc $ 52.64 -0.58 (-1.09%)
Volume:
410,731
Avg Vol (1m):
653,085
Market Cap $:
3.63 Bil
Enterprise Value $:
3.17 Bil
P/E (TTM):
0.00
P/B:
8.68
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 9.51 | ||
| Equity-to-Asset | 0.78 | ||
| Debt-to-Equity | 0.13 | ||
| Debt-to-EBITDA | -2.07 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 17.85 | ||
| Beneish M-Score | -0.74 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -41.66 | ||
| Net Margin % | -39.44 | ||
| ROE % | -21.9 | ||
| ROA % | -10.72 | ||
| ROC (Joel Greenblatt) % | -280.59 | ||
| 3-Year Revenue Growth Rate | 37 | ||
| 3-Year EBITDA Growth Rate | -2.1 | ||
| 3-Year EPS without NRI Growth Rate | -4.5 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.68 | ||
| PS Ratio | 45.58 | ||
| EV-to-EBIT | -115.42 | ||
| EV-to-EBITDA | -123.57 | ||
| EV-to-Revenue | 42 | ||
| Current Ratio | 9 | ||
| Quick Ratio | 9 | ||
| Days Sales Outstanding | 1.1 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.67 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 24.37 | ||
| Earnings Yield (Greenblatt) % | -0.87 |